Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease

A.G.N. Agustí, J.M. Villaverde, B. Togores, with the technical collaboration of M. Bosch


ABSTRACT: Excessive inflammation seems important in chronic obstructive pulmonary disease (COPD), particularly during exacerbations of the disease. Exhaled nitric oxide concentration ([NOexh]) is a sensitive marker of bronchial inflammation in asthma; it is unclear if this is also the case in COPD. This study: 1) quantifies [NOexh] in patients with COPD (during an exacerbation and while clinically stable); 2) investigates the response of [NOexh] to i.v. steroid therapy, and its potential relationship with other relevant physiological variables; and 3) assesses the relative contributions of the central and peripheral airways to [NOexh] by collecting exhaled air in two different bags connected in series.

Seventeen COPD patients (forced expiratory volume in one second (FEV1) 37.6±3.4% of the predicted value) hospitalized because of an exacerbation of COPD was quantified [NOexh]. The remaining elevated throughout recovery (37.9±4.8 ppb, p<0.001) until discharge (40.9±4.3 ppb, p<0.001). In contrast, when the patients were clinically stable (several months later), [NOexh] was significantly reduced (15.8±3.8 ppb, p<0.001), and no longer different from control values. [NOexh] was not related to any of the physiological variables measured during recovery (pulmonary gas exchange) or at discharge (forced spirometry, lung volumes, diffusing capacity). Finally, the contribution of the central and peripheral airways to [NOexh] was not different at any point in time.

These results indicate that during exacerbations of chronic obstructive pulmonary disease, the exhaled nitric oxide concentration: 1) is higher than normal; 2) is not reduced acutely by i.v. steroids but is normalized several months after discharge; 3) is unrelated to several physiological indices of disease severity; and 4) appears to be produced homogeneously in central and peripheral airways. Overall, these results are different from those reported in asthma, suggesting that different inflammatory mechanisms are operating in both diseases.


Patients with uncontrolled bronchial asthma show increased exhaled nitric oxide concentration ([NOexh]) [1]. Treatment with steroids rapidly reduce these back to normal levels, both in the outpatient setting [1, 2] and during hospitalization because of an acute asthma attack [3]. Currently, [NOexh] is viewed as a marker of pulmonary inflammation in asthma [4].

Excessive inflammation also appears to play an important pathogenic role in chronic obstructive pulmonary disease (COPD) [5–7], particularly during exacerbations [8, 9]. Yet, there is little information available regarding [NOexh] in COPD. Two recent studies showed that, at variance with asthma, [NOexh] in patients with stable COPD was minimal elevated compared to normal values and that, interestingly, the response to inhaled steroids was almost negligible [10, 11]. To date, however, there has been no systematic attempt to quantify [NOexh] in patients hospitalized because of an acute exacerbation of COPD, in which there is a burst of inflammatory mechanisms [8, 9], nor to assess [NOexh] serially during recovery, study its response to i.v. steroids [12, 13] or analyse its potential relationship with other physiological indexes of disease severity. Further, there is ongoing debate as to whether inflammation in COPD occurs mainly in central versus peripheral airways [14, 15]. It was reasoned that the use of two different bags to collect serially the exhaled air in these patients may allow the partitioning of [NOexh] in gas coming mainly from the central (first bag) or peripheral airways (second bag), in a manner quite similar to that used in the single-breath diffusing capacity of the lung for carbon monoxide DLCO measurement [16].

Accordingly, the aim of this study was to: 1) determine [NOexh] serially (on admission, during recovery, at discharge and while clinically stable) in a group of patients hospitalized because of an acute exacerbation of COPD and treated with i.v. steroids; 2) investigate the relationship
between \([\text{NO}_{exh}]\) and other variables of potential physiological interest, such as the severity of respiratory failure or the degree of airflow obstruction; and, 3) dissect the relative contribution of central and peripheral airway inflammation to \([\text{NO}_{exh}]\) in these clinical circumstances.

Material and methods

Study subjects

Seventeen male COPD patients (68.2±2.6 yrs (SEM)) who required hospitalization because of an exacerbation of the disease were studied. All of them had a significant smoking history (>30 pack-yrs); two were current smokers. In the emergency room, all had acute respiratory failure (arterial oxygen tension \((P_{\text{a,O2}})\) 7.46±0.72 kPa (56.1±5.4 mmHg); arterial carbon dioxide tension \((P_{\text{a,CO2}})\) 5.63±0.37 kPa (42.3±2.8 mmHg); pH 7.41±0.02) and, at discharge, all had severe airflow obstruction (forced expiratory volume in one second \((\text{FEV}_{1})\) 1.02±0.11 L, 37.6±3.4% of the predicted value). None of them suffered from any other concomitant disease that could potentially interfere with the diagnosis and/or clinical course. In particular, asthma, pneumonia, heart failure and cancer were specifically excluded on the basis of standard clinical, radiological and biochemical tests. During hospitalization, treatment was standardized and included oxygen, nebulized bronchodilators and i.v. steroids (methylprednisolone 40 mg·8 h⁻¹). From day 4–5, steroids were individually tapered by physicians not directly involved in the study. All patients were successfully discharged. At that point, treatment was indicated by the physician in charge. It normally included bronchodilators (β₂-agonists and/or anti-cholinergics) and inhaled steroids. A group of 10 healthy male nonsmoker volunteers (33.1±1.5 yrs) who served as controls were also studied. All participants signed their written consent after being fully informed of the nature, characteristics, risks and potential benefits of the study. This study was approved by the Research and Ethical Review Board of the Hospital Universitari Son Dureta.

Study design

During hospitalization, \([\text{NO}_{exh}]\) (and arterial blood gas levels) were measured at three different time points: within 24–48 h of hospital admission, on day 4–5 after admission, and at discharge (usually on day 9–10). Measurements were always obtained at the same time of day (~09:00). Arterial blood gas concentrations were measured while the patient was breathing the oxygen concentration that the physician in charge thought was needed (generally 24–28% via a Venturi mask (Proclínico; Montmeló, Barcelona, Spain). Conversely, in order to avoid any potential effect of oxygen therapy on \([\text{NO}_{exh}]\) [17–19], this was measured while breathing room air, at least 30 min after having stopped oxygen therapy. During this time, arterial oxyhaemoglobin saturation was continuously monitored (Criticare Systems, Inc., Waukesha, WI, USA). Each collection of expired gas (and measurement of \([\text{NO}_{exh}]\)) was performed in triplicate. Since these three measurements were not statistically different, their mean value was later used for analysis.

Originally, it was planned to study these same 17 patients while clinically stable. However, it was only possible to study 10 of them after hospitalization (three were studied at 1–2 months after discharge; the rest were studied at 6–8 months after hospitalization). Of the remaining seven patients, three individuals refused to return to the laboratory and four subjects no longer lived in the same area.

Methods

In order to measure \([\text{NO}_{exh}]\) the patient was asked to perform a slow vital capacity manoeuvre over 30–75 s into a high-resistance small diameter (4 mm) Teflon tubing system. This prevents contamination with NO from the nose cavity [20]. Similarly to in the measurement of \(DL_{CO}\) in clinical practice [16], this tubing system was connected through a two-way stopcock to two polyethylene bags of different size. The first ~500 mL of expired gas were collected in the first bag (Warren E. Collins, Braintree, MA, USA), which probably contains mainly gas from the upper and central airways (bagcaw). Without interrupting the exhalation, by switching the stopcock, the rest of the exhaled gas was collected in the second bag (Intertec Rx DABC; Mallinckrodt, Mirandola, Italy), which probably contains mainly gas from the peripheral airways (bagpaw). Both bags were assayed immediately (<10 min) after sampling for NO concentration using a chemiluminescence analyser (Dasibi Environmental Corporation, Glendale, CA, USA) sensitive to NO at 2–4,000 parts per billion (ppb, by volume). This analyser has been used by previous investigators in the field [1]. The analyser was connected to a personal computer through appropriate software (Atlantis; Lakeshore Technologies, Chicago, IL, USA), which displayed the results on-line and stored them for later analysis (Pegasus; Lakeshore Technologies). The NO analyser was calibrated before analyses with certified gas mixtures (300 ppb NO diluted in nitrogen by precision flow meters) (Abello Oxigeno Linde, Barcelona, Spain). The concentration of NO in ambient air (typically <10 ppb in Palma de Mallorca) was measured and subtracted from each NO determination. The analysis of both bags took <10 min in all cases. Preliminary experiments in the authors’ laboratory have determined the stability of NO concentrations far beyond this time (>30 min). This is in keeping with previous reports from other laboratories [10]. Also, to ensure that NO did not react with the materials that the collecting bags were made of, pilot studies compared measurements obtained after passing NO calibration gas through the tubing, connections or bags with those obtained after introducing the NO calibration gas directly into the NO analyser. These studies failed to demonstrate any significant decrease in NO concentration.

Arterial blood gas concentrations were measured in patients with COPD after radial artery puncture and local anaesthesia in a tonometrically calibrated (IL 237; Izasa, Spain) analyser (IL BG3; Izasa, Barcelona, Spain). The alveolar-arterial pressure difference for oxygen \((P_{a,\text{O2}}-P_{\text{a,O2}})\) was calculated using the standard formula, assuming a respiratory quotient \((R)\) value of 0.8 [16]. Forced spirometry (GS system, Collins, USA) was performed (at discharge) according to American Thoracic Society (ATS) recommendations [21]; static lung volumes (helium-dilution...
The reference values used were those of a GS system, Warren E. Collins) using standard techniques analysed using the Spearman rank test. A p-value was considered significant. The intra-assay coefficient of variation in [NOexh] was 30±2%.

This value is within the range reported previously in healthy subjects, using either a collecting system similar to the one used in the present study [10] or measuring NO online [20].

Data are shown as mean±SEM. Analysis of variance (followed by post hoc contrasts (Scheffe test), if appropriate) was used to investigate the statistical significance of differences. Correlations between variables of interest were analysed using the Spearman rank test. A p-value <0.05 was considered significant.

Analysis

Table 1 shows the [NOexh] in each of the two collecting bags (bagcaw and bagpaw) in patients with COPD (throughout hospitalization and while clinically stable) and in healthy controls. The concentrations in the two bags were not significantly different at any point. Therefore, for further analysis, the mean concentration in the two bags was used (table 1).

In healthy subjects, [NOexh] was 13.3±0.8 ppb (table 1). This value is within the range reported previously in healthy subjects, using either a collecting system similar to the one used in the present study [10] or measuring NO online [20].

On average, patients with COPD showed a higher [NOexh] on admission than did controls (41.0±5.1 ppb, p<0.001). As shown in figure 1, though, there was a substantial spread of [NOexh], with concentrations ranging 5.7–76.5 ppb. Interestingly, these values did not change throughout hospitalization (table 1, fig. 1). By contrast, when patients were studied in a clinically stable condition, [NOexh] was significantly lower than that measured during hospitalization (fig. 1). In fact, it was no longer different from control values (table 1). Three patients were studied earlier after discharge (at 1–2 months) than the rest (at 6–8 months). These three patients are indicated in figure 1. Interestingly, these three subjects seemed to have higher [NOexh] than did the rest. It should also be noted, however, that these three individuals were not being treated with inhaled steroids at that point in time, whereas the rest were. None of the 10 COPD patients studied in a stable condition was a current smoker.

Table 2. – Evolution of pulmonary gas exchange variables during hospitalization in all patients

<table>
<thead>
<tr>
<th>Variable</th>
<th>24–48 h</th>
<th>4–5 days</th>
<th>Discharge</th>
<th>Stable</th>
<th>COPD</th>
<th>Healthy volunteers</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1O2</td>
<td>0.26±0.01</td>
<td>0.25±0.09</td>
<td>0.21±0.04</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PaO2 mmHg</td>
<td>66.8±4.8</td>
<td>71.1±3.9</td>
<td>65.5±2.4</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PaCO2 mmHg</td>
<td>43.7±2.2</td>
<td>44.2±1.7</td>
<td>42.1±1.5</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial PH</td>
<td>7.41±0.01</td>
<td>7.42±0.01</td>
<td>7.43±0.01</td>
<td>NS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PaO2  PaCO2 mmHg</td>
<td>66.0±6.1</td>
<td>52.7±4.8</td>
<td>34.5±4.4</td>
<td>0.0001</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean±SEM (n=17) and were collected during hospitalization (24–48 h, 4–5 days, discharge). *: analysis of variance. F1O2: inspiratory oxygen fraction; PaO2: arterial oxygen tension; PaCO2: arterial carbon dioxide tension; PaO2  PaCO2: alveolar–arterial pressure difference for oxygen. **: p<0.01 versus 24–48 h; ***: p<0.01 versus 4–5 days. (1 mmHg=0.133 kPa.)
Discussion

The main findings of this study were that, in patients with severe COPD hospitalized because of an acute exacerbation of the disease, the \([\text{NOexh}]\) 1) is significantly higher than normal; 2) is neither modulated during hospitalization, nor appears to be influenced by i.v. treatment with steroids (in contrast, it is normalized several months later, when patients are considered clinically stable); 3) does not correlate with several lung function variables measured during hospitalization or at discharge; and, 4) is not different in the first and second collecting bags, suggesting that it is not different in air samples coming from the central or the peripheral airways.

Previous studies have established that \([\text{NOexh}]\) is a sensitive and reproducible marker of pulmonary inflammation in patients with bronchial asthma [1, 3, 10, 25, 26]. Much less information is available in patients with COPD [10, 11]. The present study is the first to report serial \([\text{NOexh}]\) in patients hospitalized because of exacerbated COPD. In these clinical circumstances, a burst of inflammatory mechanisms is supposed to operate [5–9]. In keeping with this postulate, it was found that many patients with exacerbated COPD had higher \([\text{NOexh}]\) than did healthy nonsmoking subjects (table 1) [3, 10], although the spread of values was significant (fig. 1). Interestingly, despite the use of i.v. steroids \([\text{NOexh}]\) remained higher than normal throughout hospitalization (table 1, fig. 1). This is at variance with what has been reported in patients with asthma [1, 3, 10, 25, 26] but in agreement with what seems to occur in stable COPD [10, 11]. Different responses to steroid treatment in asthma and COPD have also been shown in several inflammatory indexes in induced sputum [6]. Overall, thus, these observations suggest that the inflammatory mechanisms inducing the expression of NO synthase in acute asthma and exacerbated COPD are probably different [27–29]. It is also worth noting that the \([\text{NOexh}]\) measured in COPD were almost identical in the two collecting bags used at any point in time (table 1). Although the present two-bag method has not been formally validated for the partitioning of exhaled NO, by analogy to \(D_k\text{CO}\) measurements, which are based upon the same rationale, it seems fair to assume that the first bag probably contains gas from the central airways whereas the second bag contains gas from the peripheral airways. If this is accepted, then the present results suggest a similar contribution of the central and peripheral airways to \([\text{NOexh}]\) in patients with COPD, and, therefore, that the inflammatory mechanisms operating in COPD are evenly distributed through the lungs.

It has been suggested that \([\text{NOexh}]\) could be a useful surrogate marker for monitoring disease activity in stable COPD [11]. The present results indicate that this is not the case during exacerbations as, despite clinical and functional improvement (table 2), the \([\text{NOexh}]\) remained elevated through hospitalization (table 1, fig. 1). Further,
no significant correlation was found between [NOexh] and lung function during hospitalization (fig. 2) or at discharge (fig. 3). By contrast, it was remarkable that the [NOexh] was much lower under conditions of clinical stability (table 1, fig. 1) and, in fact, indistinguishable from that of control subjects, as reported previously [10, 11]. Overall, therefore, the present results indicate that [NOexh] is not useful in COPD in monitoring inflammation or guiding therapy during an episode of exacerbation, but it may indeed be a long-term marker of disease activity [11]. Importantly, these results also show that the correction of the inflammatory burst that characterizes an exacerbation in COPD is not immediate and may require several months. That [NOexh] was higher in those patients studied shortly after discharge (at 1–2 months) than in those assessed later on (at 6–8 months) (fig. 1) also supports this idea. An alternative explanation for this latter observation, though, is an effect of inhaled steroids upon [NOexh]. By chance, patients studied shortly after discharge were not treated with inhaled steroids, whereas the remaining subjects were (fig. 1). However, it is thought that this possibility is unlikely since i.v. steroids during hospitalization did not modify [NOexh] at all (table 1, fig. 1).

In order to avoid collecting NO in a reservoir, [NOexh] is normally measured on-line [20]. However, recent guidelines accept measurements made using a reservoir [20]. The latter approach was chosen because, first, it was of interest to dissect the relative contributions of the central and peripheral airways to [NOexh] in exacerbated COPD and, secondly, because it greatly facilitates the measurement of [NOexh] at the bedside. Other investigators in the field have previously used a similar system to assess the progression of [NOexh] during an episode of acute severe asthma [3]. The authors are confident that the methodology used did not influence the results. 1) As discussed in Methods, it had previously been ensured that NO readings did not change significantly within the period of time required for the analysis, and that NO did not react with the materials that the bag was made of. 2) The same system was used repeatedly to measure the [NOexh] in the patients during the progression of the disease. Therefore, the patients effectively acted as their own controls. 3) Previous studies have shown that [NOexh] are qualitatively independent of the technique used [10]. 4) Finally, the [NOexh] measured in the present study in healthy nonsmoking volunteers (table 1) are in keeping with previous published studies that used similar collecting systems [3, 10].

In summary, the present study shows that, during exacerbations of chronic obstructive pulmonary disease, the exhaled nitric oxide concentration is higher than normal, despite the use of intravenous steroids it remains elevated throughout hospitalization and it is not until several months after discharge that it normalizes fully. Further, it was found that, in the patients studied, the contribution of the central and peripheral airways to exhaled nitric oxide concentration was quite similar, suggesting that inflammation is distributed uniformity through the lungs in exacerbated chronic obstructive pulmonary disease. Overall, these results differ from those reported in asthma, further supporting the concept that the inflammatory mechanisms underlying chronic obstructive pulmonary disease and asthma are different.

Acknowledgements. The authors thank the nursing personnel of the Servei de Pneumologia (Hospital Son Dureta, Palma de Mallorca, Spain) for their help and collaboration during this study.
References


